graph Evidence gap map comparisons
atezolizumab based treatmentanti-PD-(L)1durvalumab based treatmentnivolumab based treatmentpembrolizumab based treatmentsintilimab based treatmentanti-PD-(L)1
atezolizumab plus bevacizumab atezolizumab plus cabozantinib camrelizumab based treatment durvalumab plus bevacizumab nivolumab alone pembrolizumab alone pembrolizumab plus lenvatinib sintilimab Tislelizumab
Comparator:  vs Standard of Care (SoC);   vs sorafenib;   vs placebo;   vs lenvatinib; 
Risk of bias:  low;   some concerns;   high;  NA;